Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $51.94M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 1.81M
Average 2.90M
HRTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Heron Therapeutics, Inc.NASDAQ: HRTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.39M rose 4.7% year over year, ahead of the -12.7% change in trailing-twelve-month research & development. Sequentially, it fell 36.3% from the prior quarter. Over 3 fiscal years it compounded at -46.8% a year.
Context
- Research & development amounted to 8.0% of revenue in FY2025, down 3.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.7% holds above the trailing-twelve-month pace of -12.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 12.43M USD
- Year-over-year change
- -25.5%
- 4-year CAGR
- -44.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.43M | -25.5% |
| FY2024 | 2024-12-31 | 16.68M | -57.4% |
| FY2023 | 2023-12-31 | 39.13M | -52.7% |
| FY2022 | 2022-12-31 | 82.7M | -36.8% |
| FY2021 | 2021-12-31 | 130.82M | — |
Research & Development vs competitors
How HRTX compares with its peers on the latest reported figures
- HRTX's LTM Mar 2026 research & development of $12.54M is the 9th highest of the 10 companies compared; the peer median is $27.18M.
- Its year-over-year change of -12.7% is the 7th highest of 9, against a peer median of +44.5%.
- Research & development amounts to 8.3% of revenue for HRTX, versus a peer median of 114.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.32M | +17.6% | -19.3% | 218.2% | |
| LTM Mar 2026 | $58.4M | -50.0% | -40.2% | 104.5% | |
| LTM Mar 2026 | $46.96M | +41.8% | +36.4% | — | |
| LTM Mar 2026 | $44.75M | -15.8% | -0.4% | 154.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M | +72.6% | +29.4% | — |
| LTM Sep 2026 | $23.16M | +47.2% | -19.1% | — | |
| LTM Mar 2026 | $21.52M | +58.7% | -13.4% | 28.2% | |
| LTM Mar 2026 | $16.62M | +61.4% | +12.0% | 114.8% | |
| LTM Mar 2026 | $12.54M | -12.7% | -46.8% | 8.3% | |
| LTM Mar 2026 | $3.93M | — | — | — | |
| Peer median (excluding HRTX) | $27.18M | +44.5% | -6.9% | 114.8% | |
Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 86.35M | 107.67M | 127.04M | 144.29M | 154.9M |
| Cost of Revenue | 46.02M | 54.87M | 65.11M | 38.65M | 41.35M |
| Gross Profit | 40.33M | 52.8M | 61.94M | 105.64M | 113.56M |
| Gross Margin | 46.7% | 49.0% | 48.8% | 73.2% | 73.3% |
| Research & Development | 130.82M | 82.7M | 39.13M | 16.68M | 12.43M |
| Selling, General & Admin | 127.33M | 144.75M | 119.82M | 100.48M | 103.67M |
| Operating Expenses | 258.15M | 227.46M | 172.55M | 117.17M | 116.1M |
| Depreciation & Amortization | 3.02M | 2.89M | 2.9M | 2.49M | 2.31M |
| EBITDA | (215.25M) | (176.66M) | (103.79M) | (5.06M) | (17.88M) |
| EBITDA Margin | -249.3% | -164.1% | -81.7% | -3.5% | -11.5% |
| Operating Income | (217.83M) | (174.66M) | (110.62M) | (11.53M) | (2.54M) |
| Operating Margin | -252.3% | -162.2% | -87.1% | -8.0% | -1.6% |
| Interest Income | 433K | 1.64M | 3.36M | 3.55M | 0 |
| Interest Expense | 2.41M | 2.47M | 3.87M | 6.03M | 0 |
| Other Income / Expenses | (2.86M) | (7.37M) | 56K | (2.05M) | (17.66M) |
| Income Before Tax | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Pre-Tax Margin | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (220.68M) | (182.02M) | (110.56M) | (13.58M) | (20.2M) |
| Net Margin | -255.6% | -169.1% | -87.0% | -9.4% | -13.0% |
| EPS (Basic) | (2.24) | (1.67) | (0.80) | (0.09) | (0.12) |
| EPS (Diluted) | (2.24) | (1.67) | (0.80) | (0.09) | (0.12) |
| Weighted Avg Shares | 98.47M | 109M | 138.14M | 152.45M | 166.71M |
| Weighted Avg Shares (Diluted) | 98.47M | 109M | 138.14M | 152.45M | 166.71M |
Heron Therapeutics, Inc.
NASDAQ:HRTX
Intrinsic Alpha fair value
Locked
Current Price
$0.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.